IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation

IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation

Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation antigen (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but unfortunately, patients often relapse within a yea...

Full description

Bibliographic Details
Main Authors: Anthony M. Battram, Mireia Bachiller, Victor Lopez, Carlos Fernández de Larrea, Alvaro Urbano-Ispizua, Beatriz Martín-Antonio
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
CAR-T cells
multiple myeloma
IL-2
IL-15
IL-7
BCMA
Online Access:https://www.mdpi.com/2072-6694/13/14/3534

Internet

https://www.mdpi.com/2072-6694/13/14/3534

Similar Items